semaglutide and alcohol use disorder Semaglutide… for disorder? 👀, A major 2025 randomized trial showed:, ⬇️ Heavy drinking days, ⬇️ Cravings, ⬇️ Alcohol consumption, This challenges how we think about addiction—and who might While only three medications have

Theres growing recognition that obesity and overweight are really metabolic diseases, and yet, effective therapies have been quite limited, said Dr

Real-world data from compounding pharmacies indicates that patients notice appetite suppression within 37 days of their first injection, even before significant weight loss appears on the scale

Many patients report clearer skin, improved digestion, and reduced bloating during this timeframe

The medication's influence on brain reward pathways, which overlap significantly with those controlling sexual arousal and satisfaction, may explain some of the reported changes in libido

Tumore mammario: dati osservazionali Coerentemente con questo razionale, lo studio di coorte di Dai e collaboratori (Dai et al., 2025), pubblicato su JAMA Oncology su una popolazione di 1,1 milioni di adulti con obesit o sovrappeso seguiti per un decennio, ha riportato una riduzione del rischio di carcinoma mammario del 14% nelle utilizzatrici di GLP-1 AR (hazard ratio 0,86

Clinical dosing programs in other drug areas show that at the intermediate dosage stage, 50% of patients experienced mild side effects